News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Photo taken from Antonio Passaro/LinkedIn
Oct 29, 2023, 03:16

Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2

Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn:

“ESMO23 is over and now is the time to gather my thoughts.

I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2, evaluating amivantamab plus chemotherapy with and without lazertinib, in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

The results met both of the study’s primary endpoints, showing a statistical significant and clinical meaningful improvement of PFS benefit (for both the investigational arms). Of utmost clinical significance both the amivantamab contains combinations led to a benefit in terms of intracranial PFS by BICR compared vs chemotherapy alone.

Overall, this groundbreaking achievement establishes *the new standard of care* in this challenging clinical setting, in favor of the combination of amivantamab plus chemotherapy.

I am grateful to have been part of this study, which saw our site, the Division of Thoracic Oncology of IEO (Directed by Filippo de Marinis) as the first center for accrual worldwide.

My heartfelt thanks extend to everyone who contributed to this remarkable journey: the patients and their families, dedicated caregivers, compassionate nurses, all my colleagues, and staff members involved in data collection: Giulia Sedda, Raffaella Bertolotti, Daniela Brambilla.

A special thanks to all the colleagues J and J Medical Affairs Oncology, The Janssen Pharmaceutical Companies of Johnson and Johnson. Your collective efforts have made a significant impact, shaping the future of cancer research and patient care.

The ESMOdailyReporter article.
The OncLive article.
The La Repubblica article. ”

For the trial click here.
Source: Antonio Passaro/LinkedIn

Amivantamab Antonio Passaro cancer Daniela Brambilla EGFR-mutant ESMO 2023 Filippo de Marinis Giulia Sedda lazertinib MARIPOSA-2 trial NSCLC OncoDaily Oncology osimertinib Raffaella Bertolotti
Blog
Dec 10, 2023, 18:16
Jérôme Salomon: World Health Organization is also releasing a technical manual on alcohol tax policy and administration
Insight
Dec 10, 2023, 18:12
The Cancer Research Interns (CRI) Summer Program is now accepting applications! - Train at NCI
Insight
Dec 10, 2023, 18:08
Apply for the Basic Research in Cancer Health Disparities Program - NCI Center to Reduce Cancer Health Disparities (CRCHD)
Blog
Dec 10, 2023, 18:07
Nathan Vardi: I traveled down to Maryland and spent the day at the FDA
Insight
Dec 10, 2023, 18:01
Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward
Blog
Dec 10, 2023, 17:54
Christian Rutzer: Roche and Novartis - Basel's Research and Innovation Powerhouses
Blog
Dec 10, 2023, 17:48
Nick Vitanza: It's been a dream to bring better treatments to kids with DIPG and CNS tumors
Career
Dec 10, 2023, 17:39
Dr. Salami is the winner of the American Urological Association’s prestigious Gold Cystoscope Award - YUO
Blog
Dec 10, 2023, 17:32
Wafik S. El-Deiry: I wore my chemistry tie today in honor of your visit to Providence and Brown University
Career
Dec 10, 2023, 17:26
Mark Awad was honored by GO2 for Lung Cancer at the 18th Annual Simply the Best Gala - Dana-Farber Cancer Institute
Blog
Dec 10, 2023, 17:20
Daniel Blanco: Day 1 of the 2023 St. Jude Global Alliance Convening
Blog
Dec 10, 2023, 17:10
NCI Center for Global Health on the 16th Annual Conference on the Science of Dissemination and Implementation in Health
Insight
Positive
Societies
Career